Contineum Therapeutics, Inc. (CTNM) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$13.13

From 52W high−22.99%

Volume2.14M

Market cap$509.01M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$13.13

From 52W high

−22.99%

Volume

2.14M

Market cap

$509.01M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.2x

P/E (TTM)

—

RSI (14)

36.9

MomentumView details →

1D Return

+2.42%

YTD Return

+18.81%

SummaryUpdated Jun 1, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in San Diego, California. Originally incorporated as Pipeline Therapeutics, Inc., the company rebranded to Contineum Therapeutics in November 2023. The company focuses on developing novel oral small molecule therapies targeting neurological, inflammatory, and immunological conditions with significant unmet medical needs. As a pre-revenue biotech firm, Contineum is advancing multiple drug candidates through various stages of clinical development, with its lead asset targeting both pulmonary fibrosis and multiple sclerosis.

Ask drillr about Contineum Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−24.02%

ROA (TTM)

−22.99%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+24.45%

FCF YoY

−14.28%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−33.13%

EBITDA YoY

−12.95%

MomentumView details →

1D Return

+2.42%

YTD Return

+18.81%

1Y Return

+8.64%

RSI (14)

36.9

vs 50D SMA

−10.66%

vs 200D SMA

−0.53%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

37.17x

Quick Ratio

37.17x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

10.87%

Beats (12Q)

3/12

Next Q EPS Est

−$0.45

Avg Surprise (4Q)

9.09%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−57.56M

Op. CF (TTM)

−53.01M

Next earningsOct 29, 2026 →

Latest newsMore news →

Contineum Therapeutics announced that an experimental depression drug developed with Johnson & Johnson failed to meet the main goal of a mid-stage clinical trial.6d ago

Contineum Therapeutics published a manuscript in the Journal of Medicinal Chemistry describing the discovery of its potential best-in-class LPAR1 antagonist PIPE-791.82d ago

Similar companies

Assembly Biosciences, Inc.ASMB MapLight Therapeutics, Inc.MPLT Entera Bio Ltd.ENTX XOMA Royalty Corp.XOMA Autolus Therapeutics plcAUTL Puma Biotechnology, Inc.PBYI Find similar companies →

Latest newsMore news →

Contineum Therapeutics announced that an experimental depression drug developed with Johnson & Johnson failed to meet the main goal of a mid-stage clinical trial.6d ago Contineum Therapeutics published a manuscript in the Journal of Medicinal Chemistry describing the discovery of its potential best-in-class LPAR1 antagonist PIPE-791.82d ago